Standard InChI: InChI=1S/C14H12ClNO2/c15-11-6-2-4-8-13(11)16-12-7-3-1-5-10(12)9-14(17)18/h1-8,16H,9H2,(H,17,18)
Standard InChI Key: RXRLPBIKRNGLJD-UHFFFAOYSA-N
Associated Targets(Human)
Cyclooxygenase-2 13999 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Interleukin-8 642 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Cyclooxygenase 1258 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Associated Targets(non-human)
Cyclooxygenase 304 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Rattus norvegicus 775804 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Cyclooxygenase-1 5266 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Cyclooxygenase-2 1939 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
L1.2 32 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Molecule Features
Natural Product: No
Oral: No
Chemical Probe: No
Parenteral: No
Molecule Type: Small molecule
Topical: No
First In Class: No
Black Box: No
Chirality: No
Availability: No
Prodrug: No
Drug Indications
MESH ID
MESH Heading
EFO IDs
EFO Terms
Max Phase for Indication
References
Mechanisms of Action
Mechanism of Action
Action Type
target ID
Target Name
Target Type
Target Organism
Binding Site Name
References
Properties
Molecular Weight: 261.71
Molecular Weight (Monoisotopic): 261.0557
AlogP: 3.71
#Rotatable Bonds: 4
Polar Surface Area: 49.33
Molecular Species: ACID
HBA: 2
HBD: 2
#RO5 Violations: 0
HBA (Lipinski): 3
HBD (Lipinski): 2
#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.26
CX Basic pKa:
CX LogP: 3.65
CX LogD: 0.66
Aromatic Rings: 2
Heavy Atoms: 18
QED Weighted: 0.88
Np Likeness Score: -0.95
References
1.Moser P, Sallmann A, Wiesenberg I.. (1990) Synthesis and quantitative structure-activity relationships of diclofenac analogues., 33 (9):[PMID:2118185][10.1021/jm00171a008]
2.Blobaum AL, Marnett LJ.. (2007) Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib., 282 (22):[PMID:17434872][10.1074/jbc.m609883200]
3.Sablone MR, Cesta MC, Moriconi A, Aramini A, Bizzarri C, Di Giacinto C, Di Bitondo R, Gloaguen I, Aschi M, Crucianelli M, Bertini R, Allegretti M.. (2009) Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors., 19 (15):[PMID:19560921][10.1016/j.bmcl.2009.06.027]
4.Arvind K, Solomon KA, Rajan SS. (2013) QSAR studies on diclofenac analogues as potent cyclooxygenase inhibitors using CoMFA and CoMSIA, [10.1007/s00044-013-0771-5]
5.Windsor MA, Valk PL, Xu S, Banerjee S, Marnett LJ.. (2013) Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib., 23 (21):[PMID:24060487][10.1016/j.bmcl.2013.08.097]
